Literature DB >> 9924918

Effect of type I interferon on experimental autoimmune uveoretinitis in rats.

A A Okada1, H Keino, T Fukai, J Sakai, M Usui, J Mizuguchi.   

Abstract

In order to establish a scientific basis for the potential use of type I interferons (IFNs) in clinical uveitis, we examined the effect of a preparation of IFN-alpha/beta on experimental autoimmune uveoretinitis (EAU). Lewis rats were immunized with bovine interphotoreceptor retinoid-binding protein (IRBP) and given daily intramuscular injections of 10(5) IU mouse natural IFN-alpha/beta. Intraocular inflammation was assessed by slit-lamp biomicroscopy and histopathological examination. Rats treated daily with IFN-alpha/beta starting on the day of IRBP immunization showed decreased intraocular inflammation as well as a slight delay in onset of inflammation when compared to control rats. This effect was also observed to a lesser extent in rats treated during either the induction phase of EAU only, or starting immediately after the onset of inflammation in the effector phase of EAU. Measurement of IRBP-stimulated splenocyte proliferation and serum anti-IRBP antibody subtypes did not reveal a significant difference between IFN-alpha/beta-treated rats and control rats. Measurement of cytokine production by IRBP-stimulated splenocytes in vitro showed significantly decreased TNF-alpha for IFN-alpha/beta-treated rats compared to control, but no difference for IFN-gamma, IL-2, IL-4, and IL-10. These results indicate that systemic administration of IFN-alpha/beta suppresses IRBP-induced EAU in rats, and suggest that such suppression may be mediated in part by a reduction in TNF-alpha production.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9924918     DOI: 10.1076/ocii.6.4.215.4024

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  13 in total

Review 1.  Non-infectious pediatric uveitis: an update on immunomodulatory management.

Authors:  Srilakshmi M Sharma; Andrew D Dick; Athimalaipet V Ramanan
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

2.  Interferon as a treatment for uveitis associated with multiple sclerosis.

Authors:  M D Becker; A Heiligenhaus; T Hudde; B Storch-Hagenlocher; B Wildemann; T Barisani-Asenbauer; C Thimm; N Stübiger; M Trieschmann; C Fiehn
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

3.  [Intraocular inflammation in multiple sclerosis].

Authors:  N Stübiger; K Ruprecht; U Pleyer
Journal:  Ophthalmologe       Date:  2018-06       Impact factor: 1.059

4.  Intravitreal injection of Tacrolimus (FK506) suppresses ongoing experimental autoimmune uveoretinitis in Rats.

Authors:  Keiko Oh-i; Hiroshi Keino; Hiroshi Goto; Naoyuki Yamakawa; Kouhei Murase; Yoshihiko Usui; Takeshi Kezuka; Jun-Ichi Sakai; Masaru Takeuchi; Masahiko Usui
Journal:  Br J Ophthalmol       Date:  2006-09-20       Impact factor: 4.638

Review 5.  [Uveitis in multiple sclerosis : Overview and perspectives].

Authors:  A L Hildebrandt; F Mackensen
Journal:  Ophthalmologe       Date:  2014-08       Impact factor: 1.059

Review 6.  Role of the retinal vascular endothelial cell in ocular disease.

Authors:  Arpita S Bharadwaj; Binoy Appukuttan; Phillip A Wilmarth; Yuzhen Pan; Andrew J Stempel; Timothy J Chipps; Eric E Benedetti; David O Zamora; Dongseok Choi; Larry L David; Justine R Smith
Journal:  Prog Retin Eye Res       Date:  2012-09-11       Impact factor: 21.198

7.  Upregulation of neurotrophic factor-related gene expression in retina with experimental autoimmune uveoretinitis by intravitreal injection of tacrolimus (FK506).

Authors:  Keiko Oh-i; Hiroshi Keino; Hiroshi Goto; Naoyuki Yamakawa; Masaru Takeuchi; Masahiko Usui; Takuya Iwasaki
Journal:  Br J Ophthalmol       Date:  2007-10-16       Impact factor: 4.638

8.  Interferon-alpha2a and Vogt-Koyanagi-Harada disease: a double-edged sword?

Authors:  Valerie Touitou; Damien Sene; Christine Fardeau; Thi-Huong-Du Boutin; Pierre Duhaut; Jean-Charles Piette; Phuc LeHoang; Patrice Cacoub; Bahram Bodaghi
Journal:  Int Ophthalmol       Date:  2007-02-23       Impact factor: 2.029

9.  Interferons and their potential in the treatment of ocular inflammation.

Authors:  Friederike Mackensen; Regina Max; Matthias D Becker
Journal:  Clin Ophthalmol       Date:  2009-10-19

10.  Tumor necrosis factor polymorphisms associated with tumor necrosis factor production influence the risk of idiopathic intermediate uveitis.

Authors:  Denize Atan; Jarka Heissigerova; Lucia Kuffová; Aideen Hogan; Dara J Kilmartin; John V Forrester; Jeff L Bidwell; Andrew D Dick; Amanda J Churchill
Journal:  Mol Vis       Date:  2013-01-28       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.